News & Events

Preparation underway for Phase 3 trial of AeroVanc for MRSA lung infection in people with cystic fibrosis Austin, TX – March 1, 2015 – Savara Pharmaceuticals announced today that it has closed a $20 million Series C financing round. Preparations are underway to begin a pivotal Phase 3 clinical trial of AeroVanc, the first inhaled antibiotic being developed to address...
Read more
Trial also demonstrates strong trends in secondary clinical endpoints Austin, TX – February 23, 2015 – Savara Pharmaceuticals announced today positive topline results from its Phase 2 clinical trial of AeroVanc, the first inhaled antibiotic being developed to address the growing problem of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people with cystic fibrosis (CF). AeroVanc met the primary endpoint...
Read more
Company Completes Enrollment in Phase 2 Clinical Trial Austin, TX – October 6, 2014 – Savara Pharmaceuticals announced today that it closed a $10 million bridge financing round to support the development of AeroVanc, the first inhaled antibiotic being developed to address the growing number of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in people with cystic fibrosis (CF). Previous investors...
Read more
AUSTIN, TX – December 10, 2013 – Savara Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead antibiotic product, AeroVanc, as a Qualified Infectious Disease Product (QIDP) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. The company also received Fast Track designation for AeroVanc pursuant to...
Read more
AUSTIN, TX – December 5, 2013 – Savara Pharmaceuticals announced today that the company has appointed Dr. Joseph S. McCracken, DVM and Yuri Pikover to its Board of Directors. Dr. McCracken has more than 25 years of experience in technical, business development and market development roles with biotechnology and pharmaceutical companies. Most recently he was Global Head of Business Development...
Read more